Korean Circ J.  2017 Mar;47(2):209-214. 10.4070/kcj.2016.0139.

Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease

• Yoon KL
• Lee HY
• Yu JJ
• Lee JY
• Han MY
• Kim KY
• Huh J

• KMID: 2377461
• DOI: http://doi.org/10.4070/kcj.2016.0139

Abstract

BACKGROUND AND OBJECTIVES
Intravenous immunoglobulin-SN (IVIG-SN) is a new human immunoglobulin product. Its safety is ensured by pathogen-elimination steps comprising solvent/detergent treatment and a nanofiltration process. This multicenter clinical study was designed to evaluate the efficacy and safety of combined aspirin and high-dose IVIG-SN therapy in pediatric patients with Kawasaki disease (KD).
SUBJECTS AND METHODS
We evaluated coronary artery lesions (CALs) at 2 and 7 weeks after administering IVIG-SN; total fever duration; and variations in erythrocyte sedimentation rate, N-terminal pro B-type natriuretic peptide or B-type natriuretic peptide, and creatine kinase-myocardial band level before and after treatment with IVIG-SN (2 g/kg). Adverse events were monitored.
RESULTS
Forty-five patients were enrolled, three of whom were excluded according to the exclusion criteria; the other 42 completed the study. The male:female ratio was 0.91:1, and the mean age was 29.11±17.23 months. The mean fever duration before IVIG-SN treatment was 6.45±1.30 days. Although most patients had complete KD (40 patients, 90.91%), four had atypical KD (9.09%). After IVIG-SN treatment, one patient (2.38%) had CALs, which was significantly lower than the incidence reported previously (15%) (p=0.022), but not significantly different from recent data (5%). There were no serious adverse events, though 28 patients (63.64%) had mild adverse events. Three adverse drug reactions occurred in 2 patients (eczema, anemia, and increased eosinophil count), all of which were transient.
CONCLUSION
IVIG-SN treatment in patients with KD was safe and effective.

Keyword

Kawasaki disease; Pediatric; Immunoglobulins, intravenous; Coronary artery disease

MeSH Terms

Anemia
Aspirin*
Blood Sedimentation
Clinical Study
Coronary Artery Disease
Coronary Vessels
Creatine
Drug-Related Side Effects and Adverse Reactions
Eosinophils
Fever
Humans
Immunoglobulins
Immunoglobulins, Intravenous
Incidence
Mucocutaneous Lymph Node Syndrome*
Natriuretic Peptide, Brain
Aspirin
Creatine
Immunoglobulins
Immunoglobulins, Intravenous
Natriuretic Peptide, Brain

Reference

1. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315:341–347. PMID: 2426590.

2. Lee DB. Epidemiologic study of Kawasaki disease in Korea (1976-1984). J Cath Coll. 1985; 38:8–19.

3. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics. 1978; 61:100–107. PMID: 263836.

4. Melish ME. Kawasaki syndrome. Pediatr Rev. 1996; 17:153–162. PMID: 8935914.

5. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967; 16:178–222. PMID: 6062087.

6. Taubert KA. Epidemiology of Kawasaki disease in the United States and worldwide. Prog Pediatr Cardiol. 1997; 6:181–185.

7. Yanagawa H, Kawasaki T, Shigematsu I. Nationwide survey on Kawasaki disease in Japan. Pediatrics. 1987; 80:58–62. PMID: 3601519.

8. Kim GB, Han JW, Park YW, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr Infect Dis J. 2014; 33:24–27. PMID: 24064559.

9. Nagashima M, Matsushima M, Matsuoka H, Ogawa A, Okumura N. High-dose gammaglobulin therapy for Kawasaki disease. J Pediatr. 1987; 110:710–712. PMID: 2437278.

10. Ahn SY, Hong SY, Kim NS, Lee HB, Moon SJ, Lee H. Comparison between treatment with aspirin alone and the combined treatment with aspirin and intravenous gamma-globulin in Kawasaki disease. J Korean Pediatr Soc. 1990; 33:1380–1387.

11. Kuribayashi S, Ootaki M, Tsuji M, Matsuyama S, Iwasaki H, Oota T. Coronary angiographic abnormalities in mucocutaneous lymph node syndrome: acute finding and long-term follow-up. Radiology. 1989; 172:629–633. PMID: 2772168.

12. Nakashima L, Edwards DL. Treatment of Kawasaki disease. Clin Pharm. 1990; 9:755–762. PMID: 2242655.

13. Shim SY, Heo MY, Kim HS, Sonh SJ. High-dose intravenous immune globulin retreatment in Kawasaki disease. J Korean Pediatr Soc. 2002; 45:1273–1277.

14. Witt MT, Minich LL, Bohnsack JF, Young PC. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics. 1999; 104:e10. PMID: 10390296.

15. Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr. 1994; 83:1057–1060. PMID: 7841704.

16. Kato H, Ichinose E, Yoshioka F, et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol. 1982; 49:1758–1766. PMID: 7081062.

17. Mori M, Miyamae T, Imagawa T, Katakura S, Kimura K, Yokota S. Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Mod Rheumatol. 2004; 14:361–366. PMID: 17143694.

18. Park MJ, Jeon IS, Tchah H, Cho KH, Jung MJ, Choi DY. Predictive indicators of coronary artery complications in Kawasaki disease. Korean J Pediatr. 2009; 52:1161–1166.

19. Cho KH, Kang SJ. Clinically useful predictors of resistance to intravenous immunoglobulin and prognosis of coronary artery lesions in patients with incomplete Kawasaki disease. Korean Circ J. 2014; 44:328–335. PMID: 25278986.

20. Stiehm ER. Lessons from Kawasaki disease: all brands of IVIG are not equal. J Pediatr. 2006; 148:6–8. PMID: 16423589.